Raspaglio G - Search Results

1

Stat1 confers sensitivity to radiation in cervical cancer cells by controlling Parp1 levels: a new perspective for Parp1 inhibition.

Raspaglio G, Buttarelli M, Filippetti F, Battaglia A, Buzzonetti A, Scambia G, Gallo D. Raspaglio G, et al. Cell Death Dis. 2021 Oct 12;12(10):933. doi: 10.1038/s41419-021-04229-y. Cell Death Dis. 2021. PMID: 34642300 Free PMC article.

2

Activity of cisplatin and ICI 182,780 on estrogen receptor negative ovarian cancer cells: cell cycle and cell replication rate perturbation, chromatin texture alteration and apoptosis induction.

Ercoli A, Battaglia A, Raspaglio G, Fattorossi A, Alimonti A, Petrucci F, Caroli S, Mancuso S, Scambia G. Ercoli A, et al. Among authors: raspaglio g. Int J Cancer. 2000 Jan 1;85(1):98-103. doi: 10.1002/(sici)1097-0215(20000101)85:1<98::aid-ijc18>3.0.co;2-a. Int J Cancer. 2000. PMID: 10585591 Free article.

3

Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance.

Ferlini C, Raspaglio G, Mozzetti S, Distefano M, Filippetti F, Martinelli E, Ferrandina G, Gallo D, Ranelletti FO, Scambia G. Ferlini C, et al. Among authors: raspaglio g. Mol Pharmacol. 2003 Jul;64(1):51-8. doi: 10.1124/mol.64.1.51. Mol Pharmacol. 2003. PMID: 12815160

4

Antitumour activity of the silybin-phosphatidylcholine complex, IdB 1016, against human ovarian cancer.

Gallo D, Giacomelli S, Ferlini C, Raspaglio G, Apollonio P, Prislei S, Riva A, Morazzoni P, Bombardelli E, Scambia G. Gallo D, et al. Among authors: raspaglio g. Eur J Cancer. 2003 Nov;39(16):2403-10. doi: 10.1016/s0959-8049(03)00624-5. Eur J Cancer. 2003. PMID: 14556934

5

Epidermal growth factor-responsive laryngeal squamous cancer cell line Hep2 is more sensitive than unresponsive CO-K3 one to quercetin and tamoxifen apoptotic effects.

Raspaglio G, Ferrandina G, Ferlini C, Scambia G, Ranelletti FO. Raspaglio G, et al. Oncol Res. 2003;14(2):83-91. doi: 10.3727/000000003108748630. Oncol Res. 2003. PMID: 14649542

6

Thiocolchicine dimers: a novel class of topoisomerase-I inhibitors.

Raspaglio G, Ferlini C, Mozzetti S, Prislei S, Gallo D, Das N, Scambia G. Raspaglio G, et al. Biochem Pharmacol. 2005 Jan 1;69(1):113-21. doi: 10.1016/j.bcp.2004.09.004. Biochem Pharmacol. 2005. PMID: 15588720

7

Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.

Mozzetti S, Ferlini C, Concolino P, Filippetti F, Raspaglio G, Prislei S, Gallo D, Martinelli E, Ranelletti FO, Ferrandina G, Scambia G. Mozzetti S, et al. Among authors: raspaglio g. Clin Cancer Res. 2005 Jan 1;11(1):298-305. Clin Cancer Res. 2005. PMID: 15671559

8

The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance.

Ferlini C, Raspaglio G, Mozzetti S, Cicchillitti L, Filippetti F, Gallo D, Fattorusso C, Campiani G, Scambia G. Ferlini C, et al. Among authors: raspaglio g. Cancer Res. 2005 Mar 15;65(6):2397-405. doi: 10.1158/0008-5472.CAN-04-3065. Cancer Res. 2005. PMID: 15781655

9

Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3' flanking region.

Raspaglio G, Filippetti F, Prislei S, Penci R, De Maria I, Cicchillitti L, Mozzetti S, Scambia G, Ferlini C. Raspaglio G, et al. Gene. 2008 Feb 15;409(1-2):100-8. doi: 10.1016/j.gene.2007.11.015. Epub 2007 Dec 3. Gene. 2008. PMID: 18178340

10

From plasma membrane to cytoskeleton: a novel function for semaphorin 6A.

Prislei S, Mozzetti S, Filippetti F, De Donato M, Raspaglio G, Cicchillitti L, Scambia G, Ferlini C. Prislei S, et al. Among authors: raspaglio g. Mol Cancer Ther. 2008 Jan;7(1):233-41. doi: 10.1158/1535-7163.MCT-07-0390. Epub 2008 Jan 9. Mol Cancer Ther. 2008. PMID: 18187809

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

32 results

Search Page